The Neutralization of the Eosinophil Peroxidase Antibody Accelerates Eosinophilic Mucin Decomposition

• Published in: Cells (Basel, Switzerland) Switzerland), 2023-11, Vol.12 (23), p.2746
• Main Authors: Kobayashi, Yoshiki, Chu, Hanh Hong, Bui, Dan Van, Yun, Yasutaka, Nguyen, Linh Manh, Mitani, Akitoshi, Suzuki, Kensuke, Asako, Mikiya, Kanda, Akira, Iwai, Hiroshi
• Format: Article
• Language: English
• Subjects: Airway management; Antibodies; Asthma; Autoantibodies; bronchial asthma; Care and treatment; Computed tomography; Decomposition; Diagnosis; Endoscopy; Enzymes; eosinophil; eosinophil peroxidase; eosinophilic chronic rhinosinusitis; eosinophilic mucin; Eosinophils; Health aspects; Immune system; Immunofluorescence; Immunoglobulins; Inflammation; Leukocytes (eosinophilic); Measurement; Mucin; Neutrophils; Paranasal sinus; Patient outcomes; Patients; Phosphatase; Polyps; Proteins; Respiratory tract diseases; Rhinosinusitis; Serum levels; Sinuses; Sinusitis; Steroids; Therapeutic targets; Viscoelasticity
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells12232746

Eosinophilic airway inflammation, complicated by bronchial asthma and eosinophilic chronic rhinosinusitis (ECRS), is difficult to treat. The disease may become refractory when eosinophilic mucin associated with eosinophil peroxidase (EPX) and autoantibodies fills in the paranasal sinus and small airway. This study investigated the functional role of an anti-EPX antibody in eosinophilic mucin of ECRS in eosinophilic airway inflammation. Eosinophilic mucin was obtained from patients with ECRS. The effects of the anti-EPX antibody on dsDNA release from eosinophils and eosinophilic mucin decomposition were evaluated. Immunofluorescence or enzyme-linked immunosorbent assays were performed to detect the anti-EPX antibody and its supernatant and serum levels in eosinophilic mucin, respectively. The serum levels of the anti-EPX antibody were positively correlated with sinus computed tomography score and fractionated exhaled nitrogen oxide. Patients with refractory ECRS had higher serum levels of the anti-EPX antibody than those without. However, dupilumab treatment decreased the serum levels of the anti-EPX antibody. Immunoglobulins (Igs) in the immunoprecipitate of mucin supernatants enhanced dsDNA release from eosinophils, whereas the neutralization of Igs against EPX stopped dsDNA release. Furthermore, EPX antibody neutralization accelerated mucin decomposition and restored corticosteroid sensitivity. Taken together, the anti-EPX antibody may be involved in the formulation of eosinophilic mucin and be used as a clinical marker and therapeutic target for intractable eosinophilic airway inflammation.